多发性硬化症中的间充质干细胞——向临床试验的转化
Mesenchymal stem cells in multiple sclerosis - translation to clinical trials.
作者信息
Dulamea A
机构信息
"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; "Fundeni" Clinical Institute, Bucharest, Romania.
出版信息
J Med Life. 2015 Jan-Mar;8(1):24-7.
Abstract
Multiple sclerosis is a chronic inflammatory disease of the central nervous system, characterized by an aberrant activation of the immune system and combining demyelination with neurodegeneration. Studies on experimental models of multiple sclerosis revealed immunomodulatory and immunosuppressive properties of mesenchymal stem cells. Clinical trials using mesenchymal stem cells therapy in multiple sclerosis patients showed tolerability, safety on short term, some immunomodulatory properties reducing the Th1 proinflammatory response and the inflammatory MRI parameters. The author reviews the data about experimental studies and clinical trials using mesenchymal stem cells for the treatment of multiple sclerosis.
摘要
多发性硬化症是一种中枢神经系统的慢性炎症性疾病，其特征为免疫系统异常激活，并伴有脱髓鞘和神经退行性变。对多发性硬化症实验模型的研究揭示了间充质干细胞的免疫调节和免疫抑制特性。在多发性硬化症患者中使用间充质干细胞疗法的临床试验显示出耐受性、短期安全性，以及一些免疫调节特性，可降低Th1促炎反应和炎症性MRI参数。作者综述了使用间充质干细胞治疗多发性硬化症的实验研究和临床试验数据。
相似文献
1
Mesenchymal stem cells in multiple sclerosis - translation to clinical trials.多发性硬化症中的间充质干细胞——向临床试验的转化
J Med Life. 2015 Jan-Mar;8(1):24-7.
2
Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis.间充质干细胞的免疫调节特性及其在多发性硬化症治疗中的作用。
Cell Immunol. 2015 Feb;293(2):113-21. doi: 10.1016/j.cellimm.2015.01.002. Epub 2015 Jan 10.
3
Beneficial effects of bone marrow-derived mesenchymal stem cell transplantation in a non-immune model of demyelination.骨髓间充质干细胞移植在脱髓鞘非免疫模型中的有益作用。
Ann Anat. 2015 Mar;198:11-20. doi: 10.1016/j.aanat.2014.12.002. Epub 2015 Jan 20.
4
The transplantation of mesenchymal stem cells derived from unconventional sources: an innovative approach to multiple sclerosis therapy.来源于非常规来源的间充质干细胞的移植：多发性硬化症治疗的一种创新方法。
Arch Immunol Ther Exp (Warsz). 2017 Oct;65(5):363-379. doi: 10.1007/s00005-017-0460-z. Epub 2017 Mar 25.
5
Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.间充质干细胞和诱导多能干细胞作为治疗多发性硬化症的方法。
Int J Mol Sci. 2015 Apr 24;16(5):9283-302. doi: 10.3390/ijms16059283.
6
Adipose-derived mesenchymal stem cells modulate the immune response in chronic experimental autoimmune encephalomyelitis model.脂肪来源的间充质干细胞在慢性实验性自身免疫性脑脊髓炎模型中调节免疫反应。
IUBMB Life. 2016 Feb;68(2):106-15. doi: 10.1002/iub.1469. Epub 2016 Jan 12.
7
Human Adipose Stromal/Stem Cells from Obese Donors Show Reduced Efficacy in Halting Disease Progression in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.来自肥胖供体的人类脂肪基质/干细胞在多发性硬化症实验性自身免疫性脑脊髓炎模型中阻止疾病进展的效果降低。
Stem Cells. 2016 Mar;34(3):614-26. doi: 10.1002/stem.2272. Epub 2016 Feb 2.
8
The prospect of stem cells as multi-faceted purveyors of immune modulation, repair and regeneration in multiple sclerosis.干细胞作为多发性硬化症中免疫调节、修复和再生的多面手的前景。
Curr Stem Cell Res Ther. 2011 Mar;6(1):50-62. doi: 10.2174/157488811794480735.
9
The potential use of mesenchymal stem cells for the treatment of multiple sclerosis.间充质干细胞在多发性硬化症治疗中的潜在应用。
Life Sci. 2019 Oct 15;235:116830. doi: 10.1016/j.lfs.2019.116830. Epub 2019 Sep 2.
10
Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.鞘内注射间充质基质细胞源性神经祖细胞治疗多发性硬化症的临床安全性。
Cytotherapy. 2016 Dec;18(12):1476-1482. doi: 10.1016/j.jcyt.2016.08.007. Epub 2016 Oct 7.
引用本文的文献
1
Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials.间充质基质细胞移植治疗自身免疫性和风湿免疫性疾病的疗效与安全性：随机对照试验的系统评价和荟萃分析
Stem Cell Res Ther. 2025 Feb 11;16(1):65. doi: 10.1186/s13287-025-04184-x.
2
Advances and Challenges in Spinal Cord Injury Treatments.脊髓损伤治疗的进展与挑战
J Clin Med. 2024 Jul 13;13(14):4101. doi: 10.3390/jcm13144101.
3
Peptoid-Cross-Linked Hydrogel Stiffness Modulates Human Mesenchymal Stromal Cell Immunoregulatory Potential in the Presence of Interferon-Gamma.在干扰素-γ存在的情况下，类肽交联水凝胶的硬度调节人间充质基质细胞的免疫调节潜能。
Macromol Biosci. 2024 Jul;24(7):e2400111. doi: 10.1002/mabi.202400111. Epub 2024 Apr 18.
4
Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors.间充质干细胞衍生的外泌体作为脑肿瘤治疗的新策略。
Stem Cell Res Ther. 2022 Dec 20;13(1):527. doi: 10.1186/s13287-022-03212-4.
5
Extracellular Vesicles in Musculoskeletal Regeneration: Modulating the Therapy of the Future.细胞外囊泡在肌肉骨骼再生中的作用：调节未来的治疗策略。
Cells. 2021 Dec 24;11(1):43. doi: 10.3390/cells11010043.
6
Adipose Tissue-Derived Mesenchymal Stem Cells.脂肪组织来源的间充质干细胞。
Cells. 2021 Dec 6;10(12):3433. doi: 10.3390/cells10123433.
7
Stem Cell Therapies for Progressive Multiple Sclerosis.用于进行性多发性硬化症的干细胞疗法
Front Cell Dev Biol. 2021 Jul 9;9:696434. doi: 10.3389/fcell.2021.696434. eCollection 2021.
8
Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders.间充质干细胞/基质细胞作为治疗免疫介导性疾病的有价值的来源。
Stem Cell Res Ther. 2021 Mar 18;12(1):192. doi: 10.1186/s13287-021-02265-1.
9
Latest advances to enhance the therapeutic potential of mesenchymal stromal cells for the treatment of immune-mediated diseases.增强间充质基质细胞治疗免疫介导疾病的治疗潜力的最新进展。
Drug Deliv Transl Res. 2021 Apr;11(2):498-514. doi: 10.1007/s13346-021-00934-5. Epub 2021 Feb 25.
10
Idiopathic pulmonary hemosiderosis: a review of the treatments used during the past 30 years and future directions.特发性肺含铁血黄素沉着症：对过去 30 年使用的治疗方法的回顾及未来方向。
Clin Rheumatol. 2021 Jul;40(7):2547-2557. doi: 10.1007/s10067-020-05507-4. Epub 2020 Nov 12.
本文引用的文献
1
Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.自体间充质干细胞治疗多发性硬化症的随机安慰剂对照II期试验。
PLoS One. 2014 Dec 1;9(12):e113936. doi: 10.1371/journal.pone.0113936. eCollection 2014.
2
Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study.自体间充质干细胞治疗进展性多发性硬化症：一项开放标签研究。
Curr Stem Cell Res Ther. 2012 Nov;7(6):407-14. doi: 10.2174/157488812804484648.
3
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases.间充质干细胞治疗多发性硬化症和其他神经疾病。
Lancet Neurol. 2011 Jul;10(7):649-56. doi: 10.1016/S1474-4422(11)70121-1.
4
5
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.间充质干细胞移植在多发性硬化症和肌萎缩侧索硬化症患者中的安全性和免疫效应
Arch Neurol. 2010 Oct;67(10):1187-94. doi: 10.1001/archneurol.2010.248.
6
Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.骨髓间充质干细胞移植治疗多发性硬化症患者：一项试点研究。
J Neuroimmunol. 2010 Oct 8;227(1-2):185-9. doi: 10.1016/j.jneuroim.2010.07.013. Epub 2010 Aug 21.
7
Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis.多发性硬化症患者骨髓间充质干细胞的体外扩增特性。
Mult Scler. 2010 Aug;16(8):909-18. doi: 10.1177/1352458510371959. Epub 2010 Jun 11.
8
Stem cell transplantation in multiple sclerosis.多发性硬化症中的干细胞移植。
Curr Opin Neurol. 2010 Jun;23(3):218-25. doi: 10.1097/WCO.0b013e328338b7ed.
9
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.间充质干细胞移植作为多发性硬化症治疗方法的治疗潜力：国际 MSCT 研究组共识报告。
Mult Scler. 2010 Apr;16(4):503-10. doi: 10.1177/1352458509359727. Epub 2010 Jan 19.
10
Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival.间充质干细胞分泌的超氧化物歧化酶促进小脑神经元存活。
J Neurochem. 2010 Sep;114(6):1569-80. doi: 10.1111/j.1471-4159.2009.06553.x. Epub 2010 Aug 19.
Zotero 插件